H.C. Wainwright Thinks Galectin Therapeutics’ Stock is Going to Recover

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Galectin Therapeutics (GALTResearch Report) today and set a price target of $14.00. The company’s shares closed last Thursday at $1.61, close to its 52-week low of $1.59.

According to, Arce is a 4-star analyst with an average return of 11.6% and a 39.4% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Aurinia Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Galectin Therapeutics with a $14.00 average price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $5.70 and a one-year low of $1.59. Currently, Galectin Therapeutics has an average volume of 99.35K.

Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GALT in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs targets the development of carbohdrate molecules which offers offer alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Read More on GALT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More